Hexagons on blue gradient background

Leveraging Real-Time Clinical Data to Deliver Certainty in Formulation Development: Case Studies from Across 300 Delivered Programs

Cambridge, United Kingdom | 7 November 2024
Overview

Drug product optimization is a critical development step that is common for most drugs that are progressing through today’s development pipelines to respond to suboptimal exposure profiles, to transition from an early development formulation to one suitable for chronic administration in patients, or as part of a life-cycle management strategy.

Traditional drug product optimization processes take 12-18 months to complete and place significant emphasis on the predictive power of laboratory and preclinical assessments. This approach is a non-optimal working model necessitated by the multiple disciplines required to develop, make and test new formulations in humans.

In this presentation, John McDermott will describe the application of Quotient Sciences’ Translational Pharmaceutics to re-engineer and streamline the drug product optimization process, using clinical data to improve decision-making and halve development timelines. 

Learning Objectives: 

  • Develop an understanding of Translational Pharmaceutics when applied to drug product optimization 
  • Hear case studies on reformulation programs

Date 7th November - Agenda

Registration: 10:00AM - 10:30AM
Seminar: 11:00AM – 12:00PM
Networking lunch: 01:00PM – 02:00PM

*This is an in person event that will not be recorded. A virtual option to attend is not available.

**We reserve the right, at our sole discretion, to deny registration or remove any individual who is not a confirmed current or potential client/partner of Quotient Sciences.

Register
Location
Thursday November 7th, 2024 Granta Park
Building One, Granta Centre, Great Abington, CB21 6AL
Cambridge, United Kingdom

Meet our expert:

We look forward to meeting you at our seminar taking place in Cambridge.

John McDermott

Vice President, Scientific Consulting

John McDermott is Vice President of Scientific Consulting at Quotient Sciences. John leads Quotient Sciences' global drug developm...

About John

More insight from our experts:

Read More
Drug Product, Integrated Programs, Dr. Asma Patel Accelerated pathways and CMC challenges in rare disease drug development By: Dr. Asma Patel
Learn more
Drug Product, Drug Substance, Translational Pharmaceutics, Thierry Van Nieuwenhove Interview with Thierry Van Nieuwenhove: On Quotient Sciences' Growth and Role in Accelerating Drug Development By: Thierry Van Nieuwenhove
Learn more